SUPPRESSION OF MYELOID DERIVED SUPPRESSOR CELLS AND IMMUNE CHECKPOINT BLOCKADE

Impressive responses have been observed in patients treated with checkpoint inhibitory anti-PD-1 or anti-CTLA-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Treatment with both anti-PD-1 and anti-CTLA-4 antibodies were unable to eradicate large, modestly...

Full description

Saved in:
Bibliographic Details
Main Authors Zhou, Shibin, Kinzler, Kenneth W, Vogelstein, Bert, Kim, Kibem
Format Patent
LanguageEnglish
Published 25.02.2021
Subjects
Online AccessGet full text

Cover

Loading…